ReviewActa anaesthesiologica Scandinavica2026
Mapping the Clinical Evidence on Remimazolam in Anaesthesia: A Protocol for a Scoping Review.
Review in Acta anaesthesiologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemimazolam is a recently introduced benzodiazepine used for procedural sedation and general anaesthesia. Its pharmacokinetic profile, including rapid metabolism and predictable recovery, has generated interest in its potential advantages compared with traditional sedatives such as midazolam and propofol.
methodsThis protocol follows established methodological guidance for scoping reviews. The review will map the available evidence on the clinical use of remimazolam and identify gaps in the current literature. Specifically, it will examine studied patient populations, the reported pharmacokinetic profile of remimazolam and the clinical settings in which the drug has been investigated.
resultsThe review will provide an overview of the existing literature on remimazolam, with particular focus on underrepresented patient populations, its current clinical applications, and reported short- and long-term adverse effects.
conclusionThe planned review will map the current evidence regarding remimazolam, identify underrepresented populations, the clinical contexts in which remimazolam is used, and gaps for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.